Claim Missing Document
Check
Articles

Found 3 Documents
Search

Korelasi Kadar Asam Urat dengan Derajat Keganasan Kanker Kolorektal -, Subandrate; Amalia, Ella; Setyorini, Dwi Indira; -, Safyudin
Cermin Dunia Kedokteran Vol 45, No 7 (2018): Onkologi
Publisher : PT. Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (114.654 KB) | DOI: 10.55175/cdk.v45i7.637

Abstract

Pendahuluan: Hiperurisemia pada pasien kanker meningkatkan angka kematian terutama pada stadium lanjut. Metode: Studi observasional analitik korelatif dengan rancangan cross sectional, untuk mengetahui korelasi kadar asam urat dan derajat keganasan kanker kolorektal. Subjek penelitian 35 orang penderita kanker kolorektal yang dirawat di RSUP Mohammad Hoesin (RSMH), terdiri atas 15 laki-laki dan 20 perempuan. Stadium kanker kolorektal berdasarkan pemeriksaan histopatologi di Laboratorium Patologi Anatomi RSMH/FK Unsri Palembang. Pemeriksaan kadar asam urat serum di Laboratorium Biokimia FK Unsri. Hasil: Stadium klinis penderita terdiri dari stadium II (17,1%), stadium III (48,6%) dan stadium IV (34,3%). Rata-rata kadar asam urat penderita adalah 11,8±3,5 mg/dL, 88,6% mengalami hiperurisemia. Kadar asam urat pada pasien kanker kolorektal stadium awal adalah 10,6 mg/dL, pada pasien kanker kolorektal stadium akhir adalah 12,3 mg/dL. Korelasi antara kadar asam urat dan stadium kanker kolorektal sangat lemah (r=0,072) dan tidak bermakna (p=0,647). Simpulan: Hiperurisemia terjadi pada hampir semua penderita kanker kolorektal. Kadar asam urat tidak berkorelasi dengan stadium kanker kolorektal.Introduction: Hyperuricemia in cancer patients increases mortality, especially in advanced phase. Methods: An observational analytic correlative study with cross sectional design on correlation between uric acid level and cancer stage in colorectal cancer patients. Subjects were 15 male and 20 female colorectal cancer patients treated at RSUP Mohammad Hoesin (RSMH). Stage of colorectal cancer based on histopathology examination in Anatomy Pathology Laboratory of RSMH/Medical Faculty of Sriwijaya University, Palembang. Serum uric acid level was measured in Biochemistry Laboratory of Medical Faculty of Sriwijaya University. Results: The cancer stage of the patients were stage II (17.1%), stage III (48.6%) and stage IV(34.3%). The mean uric acid levels were 11.8±3.5 mg/dL. Approximately 88.6% of colorectal cancer patients have hyperuricemia. The mean level of uric acid in patients with early stage colorectal cancer was 10.6 mg/dL, in patients with end-stage colorectal cancer was 12.3 mg/dL. The correlation between uric acid levels and colorectal cancer stage was very weak (r=0.072) and was not significant (p=0.647). Conclusion: Hyperuricemia occurs in almost all colorectal cancer patients. Uric acid level did not correlate with colorectal cancer stage. 
Identification of Mitochondrial DNA Polymorphism on Linezolid-induced Toxic Optic Neuropathy Patients Setyorini, Dwi Indira; Ahmad, Zen; Amalia, Ella; Subandrate, Subandrate; Hutabarat, Yosafat Beltsazar
Global Medical & Health Communication (GMHC) Vol 13, No 1 (2025)
Publisher : Universitas Islam Bandung

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.29313/gmhc.v13i1.14240

Abstract

Drug-resistant tuberculosis (DR-TB) is difficult to eradicate due to several factors, including insufficient treatment and medication side effects. Linezolid is among the medications with serious adverse effects. Linezolid toxicity is suspected to be related to the drug's binding to mitochondrial 16s rRNA. Some studies indicate that polymorphisms in patients' mtDNA may increase vulnerability to the development of toxic optic neuropathy. This study aims to identify a genetic influence on the vulnerability to the occurrence of toxic optic neuropathy side effects in drug-resistant tuberculosis patients receiving linezolid treatment. This research was conducted at the Faculty of Medicine, Universitas Sriwijaya, Palembang, from September to October 2023. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was undertaken to detect mutations in the G3010A mtDNA of the patients. Two patients experiencing toxic optic neuropathy side effects during drug-resistant tuberculosis treatment underwent blood sample collection. Blood samples were examined for mutations in the G3010A and A2706G genes using the PCR-RFLP method. The PCR-RFLP examination results indicated the presence of mutations in G3010A. In conclusion, polymorphism of G3010A mtDNA may contribute to the vulnerability to toxic optic neuropathy side effects in drug-resistant tuberculosis patients receiving linezolid. Further research with a larger population is needed to prove the involvement of mtDNA polymorphisms in the vulnerability to toxic optic neuropathy.
Identification of Mitochondrial DNA Polymorphism on Linezolid-induced Toxic Optic Neuropathy Patients Setyorini, Dwi Indira; Ahmad, Zen; Amalia, Ella; Subandrate, Subandrate; Hutabarat, Yosafat Beltsazar
Global Medical & Health Communication (GMHC) Vol 13, No 1 (2025)
Publisher : Universitas Islam Bandung

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.29313/gmhc.v13i1.14142

Abstract

Drug-resistant tuberculosis (DR-TB) is difficult to eradicate due to several factors, including insufficient treatment and medication side effects. Linezolid is among the medications with serious adverse effects. Linezolid toxicity is suspected to be related to the drug's binding to mitochondrial 16s rRNA. Some studies indicate that polymorphisms in patients' mtDNA may increase vulnerability to the development of toxic optic neuropathy. This study aims to identify a genetic influence on the vulnerability to the occurrence of toxic optic neuropathy side effects in drug-resistant tuberculosis patients receiving linezolid treatment. This research was conducted at the Faculty of Medicine, Universitas Sriwijaya, Palembang, from September to October 2023. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was undertaken to detect mutations in the G3010A mtDNA of the patients. Two patients experiencing toxic optic neuropathy side effects during drug-resistant tuberculosis treatment underwent blood sample collection. Blood samples were examined for mutations in the G3010A and A2706G genes using the PCR-RFLP method. The PCR-RFLP examination results indicated the presence of mutations in G3010A. In conclusion, polymorphism of G3010A mtDNA may contribute to the vulnerability to toxic optic neuropathy side effects in drug-resistant tuberculosis patients receiving linezolid. Further research with a larger population is needed to prove the involvement of mtDNA polymorphisms in the vulnerability to toxic optic neuropathy.